ACAT · NP Life Sciences Health Industry Group Inc.
$10.00
At close · Oct 24
Going-concern doubt
— flagged Apr 16, 2024
Substantial doubt about the company's ability to continue as a going concern.
“The circumstances give rise to substantial doubt to the Company's ability to continue as a going concern within one year after the date that the financial statements are issued, and in order to remain solvent that the Company is dependent upon its ability to generate sufficient revenues to operate profitably or raise additional capital through debt financing and/or through sales of common stock. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides an opportunity for the Company to continue as a going concern.”View the 10-K filed Apr 16, 2024
Market Cap
$42.96M
Shares
4.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.00
Open$10.00
Day$10.00–10.00
Available close range$10.00–10.00
Avg vol 30d158
DataOct 2020–Oct 2025
Filing10-K · Apr 16
The closing range uses available history since Oct 24, 2025; less than a full year is stored.
Up next
filed Apr 16, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$164,621
Trailing 12 months
Net income (TTM)
−$2,935
Trailing 12 months
Revenue growth YoY
+61.4%
Year over year
Operating margin
-0.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$70,614
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
RSI (14)
63
neutral
MACD trend
Positive
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+5%
trailing
YTD return
+1755%
this year
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
4493%
annualized · 1-yr
Max drawdown
−96%
past year
ATR
18.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its available closing range
Price range unavailable — no recent comparable closes.
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Information Technology Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACAT
this stock
NP Life Sciences Health Industry Group Inc.
|
$42.96M | — | +61.4% | — | — |
|
IBM
International Business Machines Corp
|
$223.99B | -22.5% | +7.6% | 21.1 | 2.3% |
|
ACN
Accenture plc
|
$129.15B | -32.4% | +7.4% | 15.5 | 3.8% |
|
INFY
Infosys Ltd
|
$44.84B | -39.3% | — | — | 3.2% |
|
CTSH
Cognizant Technology Solutions Corp
|
$29.62B | -27.9% | +7.0% | 13.6 | 7.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACAT | +233.3% | +5.3% | — | +1755.3% | +1755.3% |
| SPY | +1.9% | +2.3% | +20.2% | +1.7% | +15.6% |
| vs SPY | +231.4% | +2.9% | — | +1753.6% | +1739.7% |